Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

49.43USD
13 Sep 2019
Change (% chg)

$-0.18 (-0.36%)
Prev Close
$49.61
Open
$49.95
Day's High
$50.34
Day's Low
$49.28
Volume
1,663,741
Avg. Vol
2,636,629
52-wk High
$63.69
52-wk Low
$42.49

Select another date:

Thu, Sep 5 2019

UPDATE 1-Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Sept 5 Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Aug 26 Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

NEW YORK Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

NEW YORK, July 25 Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

NEW YORK, July 25 Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers releases mixed Opdivo lung cancer results

NEW YORK Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

Bristol-Myers releases mixed Opdivo lung cancer results

NEW YORK, July 24 Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion (58 billion pounds) deal.

UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

June 24 Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.

Select another date: